Qiagen launches advanced QIAstat-Dx respiratory panel in Malaysia

Qiagen has introduced an improved version of its QIAstat-Dx Respiratory SARS-CoV-2 Panel in Malaysia, following approval by the Medical Device Authority (MDA).

This new version, which holds a CE-IVD mark, increases its detection capability from 22 to 23 pathogens and is compatible with the QIAstat-Dx Rise system, a high-capacity variant of the QIAstat-Dx automated syndromic system.

This upgraded panel is a multiplexed nucleic acid real-time PCR test designed for the qualitative detection of common pathogens presenting with influenza-like symptoms. It now can detect and differentiate among 23 viral and bacterial targets, including Chlamydophila pneumoniae.

The QIAstat-Dx system, intended for laboratory use, utilises cost-efficient, single-use cartridges with built-in sample processing and on-board reagents. By employing multiplex real-time PCR, it can detect and differentiate multiple pathogens, delivering results in about an hour. This rapid and accurate testing allows healthcare providers to make informed clinical decisions swiftly, facilitating timely therapeutic interventions, especially crucial for managing upper respiratory tract infections (URTIs).

QIAstat-Dx solutions and syndromic tests are available in over 100 countries globally. The systems have been installed in various hospitals, including those under the Malaysian Ministry of Health, with the first installation in 2019. QIAstat-Dx is available in two formats: the QIAstat-Dx Analyzer, which integrates up to four Analytical Modules, and the higher-capacity QIAstat-Dx Rise, which can conduct up to 160 tests per day using eight Analytical Modules.